STOCK TITAN

Novavax (NVAX) director exercises RSUs for 9,520 common shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Novavax Inc. director Charles W. Newton acquired common shares through an RSU-related transaction. On April 25, 2026, he exercised derivative rights linked to Restricted Stock Units (RSUs), resulting in ownership of 9,520 shares of Novavax common stock held directly after the transaction.

Each RSU represents a contingent right to receive one share of Novavax common stock. According to the grant terms, the RSUs will vest in three equal annual installments, with one-third of the RSUs scheduled to vest on each of the first three anniversaries of April 25, 2025, subject to his continued service on the company’s Board of Directors.

Positive

  • None.

Negative

  • None.
Insider Newton Charles W.
Role null
Type Security Shares Price Value
Exercise Restricted Stock Units 9,520 $0.00 --
Exercise Common Stock 9,520 $0.00 --
Holdings After Transaction: Restricted Stock Units — 19,040 shares (Direct, null); Common Stock — 9,520 shares (Direct, null)
Footnotes (1)
  1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Company common stock. The RSUs subject to this grant under the Plan will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of April 25, 2025, in each case subject to continued service on the Company's Board of Directors through such vesting date.
Common shares acquired 9,520 shares Shares received via derivative exercise on April 25, 2026
Common shares held after 9,520 shares Direct ownership following reported transactions
RSUs in transaction 9,520 RSUs Restricted Stock Units linked to common stock conversion
RSU vesting start date April 25, 2025 First of three annual vesting anniversaries
RSU vesting pattern One-third per year Vests on first three anniversaries of April 25, 2025
Restricted Stock Units financial
"The RSUs subject to this grant under the Plan will vest with respect to one-third"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
RSU financial
"Each restricted stock unit ("RSU") represents a contingent right to receive one share"
Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.
contingent right financial
"represents a contingent right to receive one share of Company common stock"
vest financial
"The RSUs subject to this grant under the Plan will vest with respect to one-third"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
continued service financial
"subject to continued service on the Company's Board of Directors through such vesting date"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Newton Charles W.

(Last)(First)(Middle)
C/O NOVAVAX, INC.
21 FIRSTFIELD ROAD

(Street)
GAITHERSBURG MARYLAND 20878

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
NOVAVAX INC [ NVAX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/25/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/25/2026M9,520A$09,520D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units$0(1)04/25/2026M9,520 (2) (2)Common Stock9,520$0.0019,040D
Explanation of Responses:
1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Company common stock.
2. The RSUs subject to this grant under the Plan will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of April 25, 2025, in each case subject to continued service on the Company's Board of Directors through such vesting date.
/s/ Mark J. Casey, Attorney-in-Fact04/28/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Novavax (NVAX) director Charles W. Newton report?

Charles W. Newton reported acquiring Novavax common stock through an RSU-related exercise. He now directly holds 9,520 shares of common stock after converting Restricted Stock Units, according to the Form 4 insider filing for the April 25, 2026 transaction date.

How many Novavax (NVAX) shares does Charles W. Newton hold after this Form 4?

After the reported transactions, Charles W. Newton directly holds 9,520 shares of Novavax common stock. This position reflects shares received through the exercise or conversion of derivative securities linked to Restricted Stock Units on April 25, 2026.

What are the terms of Charles W. Newton’s Novavax (NVAX) RSU grant?

Each RSU represents a contingent right to receive one Novavax common share. The RSUs vest in three equal installments, with one-third vesting on each of the first three anniversaries of April 25, 2025, subject to his continued service on the Board of Directors.

Did the Novavax (NVAX) Form 4 report a stock sale by Charles W. Newton?

The Form 4 does not report any open-market stock sales by Charles W. Newton. It shows derivative exercises related to Restricted Stock Units, which increased his direct holdings of Novavax common stock to 9,520 shares following the April 25, 2026 transactions.

How many Restricted Stock Units were involved in Charles W. Newton’s Novavax (NVAX) transaction?

The filing shows 9,520 Restricted Stock Units tied to the derivative transaction, each convertible into one Novavax common share. These RSUs are subject to a vesting schedule based on three annual installments beginning on April 25, 2025.